Congenital heart malformations, also known as congenital heart defects (CHDs), encompass a spectrum of structural abnormalities in the heart that manifest at birth, originating during fetal development. These defects impact various components of the heart, including its walls, valves, and blood vessels, leading to disruptions in normal blood flow. The severity of CHDs can vary, with some posing minimal health risks while others demand immediate medical attention. The etiology of congenital heart malformations is multifaceted, involving a complex interplay of genetic factors, environmental influences, or a combination thereof. Recent strides in medical technology have revolutionized the landscape of prenatal screening, enabling the early detection of congenital heart malformations. This breakthrough facilitates timely intervention and treatment strategies, ultimately enhancing patient outcomes. Treatment approaches are diverse, tailored to the specific defect and its severity. They range from pharmaceutical interventions to intricate surgical procedures aimed at rectifying the structural anomalies.
Title : Personalized and precision medicine (PPM) as a unique healthcare model through biodesign-driven translational applications and cardiology-related healthcare marketing to secure the human healthcare and biosafety
Sergey Suchkov, N.D. Zelinskii Institute for Organic Chemistry of the Russian Academy of Sciences, Russian Federation
Title : Beyond weight loss and diabetes control GLP 1 agonists paradigm shift in Cardiovascular care .
Syed Raza, Awali Hospital, Bahrain
Title : Vericiguat Inhibits the Progress of Cardiac Hypertrophy and Prevents Hypertrophy Induced Heart Failure by Multiple Mechanisms
Guo Wei He, TEDA International Cardiovascular Hospital, Tianjin University, China
Title : Coronary revascularization in patients with diabetes: Prospects for stenting in patients with type 1 diabetes and coronary artery disease
Mekhman N Mamedov, National Research Center for Therapy and Preventive Medicine, Russian Federation
Title : STEMI versus acute occlusive myocardial infarction: Which term should we use?
Yochai Birnbaum, Baylor College of Medicine, United States
Title : Chronic angina and the health economics of cardiovascular risk reduction in macro- and microvascular coronary disease
Uwe Peter Tigor, Auxilius Pharma, United States